Form 4: Werewolf Therapeutics Director Granted 27,000 Stock Options

Luke Evnin, a Director at Werewolf Therapeutics, Inc., was granted 27,000 stock options with an exercise price of $1.29, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Summary

• Luke Evnin, a Director of Werewolf Therapeutics, Inc. (HOWL), was granted 27,000 stock options.
• The options have an exercise price of $1.29 per share.
• The grant date for these options was June 12, 2025.
• The options vest in full on the earlier of June 12, 2026 (first anniversary of grant date) or the next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Mr. Evnin's continued service as a director.
• The options expire on June 11, 2035.
• Following this transaction, Mr. Evnin directly beneficially owns 27,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns management's interests with shareholders and incentivizes long-term performance. It's a standard compensation practice.

Positives

• Granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The exercise price of $1.29 suggests a potential belief in future stock price appreciation above this level.

Risks

• The value of the stock options is dependent on the future stock price of Werewolf Therapeutics, Inc. If the stock price does not exceed the exercise price of $1.29, the options may expire worthless.
• Vesting is subject to continued service as a director, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The granting of stock options with a future vesting schedule indicates an expectation of continued service from the director and aligns their incentives with the company's long-term performance.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, used to attract and retain talent and align interests with long-term company growth and shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of director compensation across various industries, including biotechnology. The specific terms (exercise price, vesting schedule) would typically be benchmarked against peer companies of similar size and stage within the biotech sector to ensure competitive compensation and appropriate incentive alignment. Without specific peer data, a direct comparison of the grant's size or terms is not possible, but the mechanism itself is standard.

Stakeholder Impact

• Shareholders: Potential positive impact as director's interests are aligned with stock price appreciation.

Next Steps

• Monitoring the company's stock performance relative to the $1.29 exercise price.
• Observing the vesting of the options on or after June 12, 2026, or the next annual meeting.

Key Dates

Recommendation

Keywords

Werewolf Therapeutics, HOWL, Stock Option, Director Compensation, Insider Trading, SEC Form 4, Equity Grant, Executive Compensation, Biotechnology, Pharmaceuticals